Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis

Exclusion Criteria

• •Young ages \<18 years
• •Secondary causes of hepatic fat accumulation such as Significant alcohol consumption as defined by an average daily consumption of alcohol greater than 30 g/day in men and greater than 20 g/day in women or Long-term use of a steatogenic medication (e.g., non-Steroidal anti-inflammatory drugs (NSAIDs) amiodarone, methotrexate, tamoxifen, corticosteroids)
• •Patients with a known history of viral hepatitis, hemochromatosis, Wilson's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction.
• •Patients with inflammatory diseases.
• •Subjects using any other lipid-lowering agents, or any supplements known to have antioxidant activity and omega-3 supplementation for at least 3 months before participation in the trial
• •Current Pregnancy
• •Breastfeeding
• •Females On Oral Contraceptive pills
• •Patients with renal impairment
• •Patients with heart failure
• •Patients with cancer or with a history of cancer treatment
• •Any contraindications to coenzyme Q 10 Or statins like hypersensitivity to anyone
• •Patients with predisposing risk factors for myopathy/rhabdomyolysis.